Previous laboratory studies have reported a significant anti-tumor effect of a histone-deacetylase (HDAC) inhibitor Vorinostat using the C666-1 NPC cell line as the main experimental target [14]. The gene discussed is HDAC9; the disease is nasopharyngeal carcinoma.